Anacetrapib lowers the bad stuff, too, new test indicates
CHICAGO — An experimental drug shows the ability to more than double a person’s good cholesterol score, potentially filling a huge gap in cardiovascular care, scientists report. If the findings hold up in a larger trial, the drug, called anacetrapib, stands poised to become the best medication yet for boosting levels of the heart-disease preventer HDL.
“This is a very exciting era we are entering,” said Christopher Cannon, a cardiologist at Harvard Medical School and Brigham and Women’s Hospital in Boston. He presented the findings at a meeting of the American Heart Association on November 17, the same day they appeared online in the New England Journal of Medicine.
“These preliminary data are very promising,” agreed Sidney Smith, a cardiologist at the University of North Carolina at Chapel Hill and a past president of the AHA. “They show dramatic differences in HDL.” High-density lipoprotein, or HDL, u